Video

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

Author(s):

Erica Bell, PhD
Conference|ASCO Annual Meeting

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Related Content
Malignant Glioma
November 7th 2024

FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

FDA
October 24th 2024

FDA Grants Priority Review to TLX101-CDx for Glioma Imaging

Panna Sharma
October 15th 2024

FDA Grants Fast Track Designation to LP-184 for Glioblastoma

Randall B. Riggs, MBA
October 11th 2024

FDA Grants Orphan Drug Designation to LMP744 for Glioma

MTX110 in Recurrent Glioblastoma | Image Credit: © Dr_Microbe - stock.adobe.com
October 4th 2024

MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma